Shanghai Henlius Biotech, Inc. (HKG:2696)

Market Cap	17.96B
Revenue (ttm)	6.09B
Net Income (ttm)	873.12M
Shares Out	543.49M
EPS (ttm)	1.61
PE Ratio	20.57
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,241,900
Average Volume	1,649,129
Open	34.30
Previous Close	34.00
Day's Range	31.95 - 34.30
52-Week Range	13.74 - 36.80
Beta	0.85
RSI	58.16
Earnings Date	Mar 23, 2025

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,515
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2696

Financial Performance

In 2024, Shanghai Henlius Biotech's revenue was 5.72 billion, an increase of 6.11% compared to the previous year's 5.39 billion. Earnings were 820.47 million, an increase of 50.26%.

Financial numbers in CNY